tbuckley/cabot-search huggingface dataset:
Abstract 16913: Cardiac Magnetic Resonance Versus Routine Catheterization Prior to Bidirectional Glenn Operation: Long-Term Follow-Up of a Randomized Clinical Trial
Authors: David W Brown, Kimberlee Gauvreau, Andrew J Powell, Peter Lang, Steven D Colan, Pedro J del Nido, Kirsten C Odegard, Tal Geva
Journal: Circulation (2011)

Background: A previously published randomized clinical trial of cardiac magnetic resonance (CMR) versus routine catheterization in patients with functional single ventricle (SV) prior to Glenn operation (BDG) demonstrated similar short-term post-operative outcomes. We sought to evaluate late outcomes in this cohort to ascertain any long-term effects of this management strategy. Methods: Retrospective review of enrolled patients through most recent follow-up. Results: Follow-up was available on all 82 patients in the original cohort, median age 6.5 years at most recent follow-up. Of these, 76 (93%) underwent Fontan operation; 2 died prior to Fontan. Baseline demographics, anatomic factors, and age at BDG did not differ between those randomized to CMR versus catheterization. Although CMR patients were slightly younger at Fontan operation (2.4 vs 2.7 years, p=0.02), baseline weight, body surface area, and oxygen saturation at time of Fontan were similar. Echocardiographic data prior to Fontan were similar, with 2 patients in each group having ≥ moderate ventricular dysfunction, and only 1 patient with ≥ moderate atrioventricular valve regurgitation. Catheterizations were performed in all patients prior to Fontan (n=76). Although age at catheterization was younger in the CMR group (2.3 vs 2.7 years, p=0.003), hemodynamic parameters were not significantly different, including pulmonary vascular resistance, mean pulmonary artery, atrial, and ventricular end-diastolic pressures. Prevalence of coarctation and pulmonary artery stenoses were similar. Patients in the CMR group had a similar rates of transcatheter interventions (71 vs. 79%, p=0.6) including similar rate of coil occlusion of aorto-pulmonary collaterals (66 vs. 61%, p=0.29). At time of Fontan, short-term complications, hospital length of stay, and the percent of patients meeting a 5-part definition of a successful Fontan operation were not significantly different (71 vs 55%, p=0.23). Conclusions: The CMR and catheterization groups had equivalent clinical and hemodynamic profiles prior to Fontan, and similar post-Fontan outcomes at a median follow-up of 6 years post BDG. For selected patients, a pre-BDG evaluation with CMR is an acceptable alternative to catheterization.
Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring.
Authors: Ahmad A. Tarhini, Howard Edington, Lisa H. Butterfield, Hussein Tawbi, Stergios J. Moschos, Yongli Shuai, Yan Lin, Mary Horak, Saro Sarkisian, Janice Shipe-Spotloe, Christy Milburn, Cindy Sander, Jonas Talmadge Johnson, John M. Kirkwood
Journal: Journal of Clinical Oncology (2012)

8533 Background: Neoadjuvant ipilimumab (ipi) for stage IIIB-C melanoma may improve the clinical outcomes and provide access to pre/post ipi blood and tumor to gain insight into host effector and suppressor immune response mechanisms. Methods: Patients were treated with ipi (10 mg/kg IV q3weeks x 4doses total) bracketing definitive surgery. Tissue samples were obtained at baseline and at definitive surgery (week ≥ 6) and serum/PBMC collected at baseline, 6 weeks, then at 3, 6, 9, 12 months and/or progression. Flow cytometry was used to monitor the host effector and suppressor immune response in blood and evaluable tumor. Results: Thirty pts (21 male, 9 female), age 40-87 were enrolled (25 cutaneous primary, 1 unknown, 4 mucosal). Six had AJCC stage IIIB (N2b, N2c) and 24 IIIC (N3) melanoma. Ninety-three cycles have been delivered (median 4). Worst toxicities included grade 3 diarrhea/colitis (5 patients; 17%), hepatic enzyme elevations (2; 7%), rash (2; 7%), lipase (1; 3%), all manageable. Median follow up is 14 months: among 29 evaluable pts 15 (52%) continue disease free. Median PFS is 15.5 months, 95% CI = (8.1,-). The probability of 6 and 12 month PFS is 82.4% (95% CI=0.63, 0.92) and 53% (95% CI=0.31, 0.70) respectively. Peripherally, a significant increase in frequency of circulating T-regs (CD4+CD25hi+ Foxp3+; p=0.02 CD4+CD25hi+CD39+; p=0.001) from baseline to 6 weeks was observed. Greater increases in T-regs were associated with improved PFS (p=0.045; HR=0.54). Significant decreases in circulating MDSCs, were observed in monocytic HLA-DR+ / low/CD14+ MDSC subtype (p&lt;0.0001). Spontaneous in vivo cross presentation was observed resulting in Th1 CD4 and CD8 antigen specific T-cell immunity (gp-100, MART-1, NY-ESO-1 peptides) with increase in frequency after ipi. Activated TIL in tumor increased after ipi (CD3+/CD4+/CD69+;p=0.06 and CD3+/CD8+/CD69+) with significant induction/potentiation of T-cell memory (CD8+/CD45RO+/TNF-α+;p=0.03). Conclusions: Neoadjuvant ipi exhibits promising clinical activity and significantly modulates the host effector and suppressor immune response. Full analysis of this completed trial and its correlates will be presented. Support: BMS, P30CA047904 and P50CA121973.
SAT0250 The dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis – a randomized controlled study
Authors: T. Weitoft, K. Öberg
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Intra-articular glucocorticoid (IAGC) injection treatment is an easy and effective way to treat signs and symptoms of arthritis and it has been used for decades. Serious adverse reactions are rare, but IAGC therapy has impact on endocrine balances. There is limited knowledge of the adequate dosing for different joints and dosing traditions vary all over world. <h3>Objectives:</h3> To compare the relapse rate during 6 months after IAGC for knee synovitis, between two common doses (20 mg vs 40 mg) of triamcinolone hexacetonide (THA). <h3>Methods:</h3> A total of 159 adult patients with rheumatoid arthritis (RA) or psoriatic arthritis (Psoa) and active knee synovitis were randomized to IAGC injection with either 20 mg or 40 mg THA blinded to the participants. The primary endpoint was relapse of arthritis. When symptoms from the treated joint recurred and signs of arthritis could be confirmed on a following clinical examination a relapse was recorded and days from injection to relapse was calculated. At the end of the observation period those without relapse had a phone call to verify persistence of good treatment response. <h3>Results:</h3> In this material there was no significant difference in patient characteristics at baseline and the proportion of relapse after 6 months were equal in the treatment arms (30% versus 32%, p=0.822). Additionally no significant differences were found in the subgroups with RA and Psoa patients. <h3>Conclusions:</h3> To reduce the risk for endocrine side effects and as no difference in treatment outcome between the compared doses was found the lower 20 mg THA dose should be preferred in IAGC treatment for knee synovitis in chronic polyarthritis. <h3>Disclosure of Interest:</h3> None declared
葡萄球菌的治疗——选择用药应是整体方案中的一部分，其中包括控制感染
Authors: Sebastian, Amyes, 范洪伟（译）, 王爱霞（校）
Journal: BMJ (2005)

在过去的5年中，我们发现多重耐药的金黄色葡萄球菌（通常称为耐甲氧西林金黄色葡萄球菌——MRSA）在英国的医院和疗养院迅速增加。耐药性首次出现时多是由于基因突变或不同种金黄色葡萄球菌问基因转移造成，当前耐药菌的出现和传播不再简单局限于此。相反，目前的耐药性是少数克隆株播散造成，这些克隆株具有耐药倾向，并已经由目前的治疗筛选出来。那么该如何治疗葡萄球菌感染呢？
Response by Weinberg et al to Letter Regarding Article, “Carotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease)”
Authors: Ido Weinberg, Joshua A. Beckman, Yu Shu, Michael R. Jaff
Journal: Circulation (2018)
SAT0184 The effect of smoking on response to tumor necrosis factor-alpha inhibitor treatment in ankylosing spondylitis patients: results from the turkbio registry
Authors: H. Yarkan Tuğsal, G. Can, S. Çapar, B. Zengin, G. Kenar, S. Akar, E. Dalkiliç, S. şenel, S. S. Koca, A. Tufan, A. Yazici, N. İnanç, H. Ellidokuz, N. Akkoç, F. Önen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Although there is good evidence that smoking has a dose-dependent impact on structural damage progression in ankylosing spondylitis (AS) the evidence is poor for its impact on disease activity, physical mobility, life quality and treatment response. <h3>Objectives:</h3> We aimed to investigate the impact of smoking on disease acitivity, treatment adherence and treatment response in Turkish patients with AS treated with their first tumour necrosis factor-alpha inhibitor (TNFi) therapy in a real-life cohort. <h3>Methods:</h3> 561 patients fulfilling the modified New York criteria for AS and treated with their first TNFi therapy since 2011 from 8 centers in Turkey were included in the analysis. Treatment response was evaluated as achievement of "BASDAI50" or "ASDAS Clinically important improvement (CII)" at the 3-months' and 6 months' visits. Clinical and demographic parameters were compared between current/never and current/previous smoker groups. Demographic and descriptive data are presented by medians/interquartile ranges (IQRs). Groups were compared by non- parametric tests (x<sup>2</sup>, Kruskal Wallis and Mann Whitney tests). Kaplan Meier plots, Cox and logistic regression analyses were calculated for treatment adherence and treatment response. <h3>Results:</h3> Among 561 AS patients included in the study, 506 (90%) had known smoking status (37% current, 35% never, 17% previous smokers). The median follow-up time was 1.9 years (IQR 0.85–3.5) and disease duration was 3.1 years (0,6–7,7). At baseline, current smokers were younger (34, IQR 29–41) compared with never (38, IQR 30–46 p=0.007) and previous smokers (42, IQR 34–49 p&lt;0,001). Current smokers had male predominance (n=148, 43.9%; n=85, 25.2%); lower erythrocyte sedimentation rate (28 mm/h (13–42); 34 mm/h, (20–49) and higher change in BASMI (40, IQR 10–57.5; 10, IQR 4–30) compared with never smokers (all p&lt;0.005). HLA status, body mass index, CRP, baseline disease indexes (BASDAI, BASFI, BASMI, HAQ, ASDAS) and treatment response was not found to be different between current and never smoker patients in our population (table 1). In multivariate analysis, male (OR:1,98; 95% CI (1,39–2,82), p&lt;0,01), HLA positive (OR:1,54; 95%CI (1,08–2,18), p=0,016) and active DMARD user (OR:1,84; (95%CI 1,12–3,01) p=0,015) patients had better treatment response and treatment adherence ((HR:1,93; 95% CI (1,36–2,73); HR:1,60; 95% CI (1,13–2,27); HR:1,80; 95% CI (1,10–2,95) all p&lt;0,005) but smoking status were not significant (p&gt;0,05). <h3>Conclusions:</h3> In this study of TNFi-treated AS patients in clinical practice, smoking was not found to be associated with disease activity, treatment response and treatment adherence. <h3>Disclosure of Interest:</h3> None declared
Prospective study of the effects of adjuvant breast cancer chemotherapy on taste function and food hedonics.
Authors: Anna Boltong, Sanchia Aranda, Russell Keast, Rochelle Wynne, Prudence A. Francis, Jacqueline H. Chirgwin, Karla Gough
Journal: Journal of Clinical Oncology (2013)

e20536 Background: "Taste changes" are commonly reported by people receiving chemotherapy. It is unclear to what extent this relates to altered taste function or changes to other aspects of the eating and drinking experience such as food liking or appetite. Methods: Women (n = 52) prescribed adjuvant chemotherapy underwent testing of taste perception, appetite and food liking before, during and after chemotherapy. Taste sensitivity was measured by correct or incorrect identification of prototypical tastants sweet, salt, sour, bitter and umami. Perceived intensity of each tastant was measured on a 10cm Visual Analogue Scale. Liking of standard sweet and savory foods was measured on the 9-point hedonic scale. Appetite was measured on a 10-point scale. McNemar’s test was used to determine whether proportion of correctly identified tastants changed significantly from baseline at follow-up assessments. Mixed-effects models were used to estimate and test change in mean taste intensity, food liking and appetite from baseline at follow-up assessments. Results: Significant adverse effects were observed for taste identification, liking of sweet food and appetite close to chemotherapy administration. Notably different patterns of change were observed for identification of individual tastants. Conclusions: The demonstrated changes in taste function and food hedonics could be used to guide pre-chemotherapy education and have implications for dietary choice and nutritional outcomes. [Table: see text]
Orlistat 복용과 관련된 급성 담즙정체성 간염 유발 증례
Authors: 김도현(Doh Hyun Kim), 이은희(Eun Hee Lee), 황재철(Jae Chul Hwang), 정재학(Jai Hak Jeung), 정재연(Jae Youn Cheong), 김원석, 조성원(Sung Won Cho), 김영배(Young Bae Kim)
Journal: Clinical and Molecular Hepatology (2002)

Orlistat(Xenical?, Roche) is considered a safe and effective drug to treat obesity by reduced absorption of 30% digested fat. To date, no serious adverse effects affecting the liver have been published except a case of subacute hepatic failure leading to liver transplantation in a young women with moderate obesity treated with orlistat. We report a case of acute cholestatic hepatitis in a young woman with moderate obesity treated with orlistat: a 33-year-old female admitted for the evaluation of jaundice. Abdominal ultrasonography, ERCP, routine chemistry, viral markers, and a fine needle biopsy of liver were performed. Microscopic findings of the liver biopsy specimen were compatible with acute cholestatic hepatitis. After steroid therapy, liver function was improved. (Korean J Hepatol 2002;8:317-320)
Exercise and pregnancy in recreational and elite athletes: 2016/2017 evidence summary from the IOC expert group meeting, Lausanne. Part 5. Recommendations for health professionals and active women
Authors: Kari Bø, Raul Artal, Ruben Barakat, Wendy J Brown, Gregory A L Davies, Michael Dooley, Kelly R Evenson, Lene A H Haakstad, Bengt Kayser, Tarja I Kinnunen, Karin Larsen, Michelle F Mottola, Ingrid Nygaard, Mireille van Poppel, Britt Stuge, Karim M Khan
Journal: British Journal of Sports Medicine (2018)

Exercise and pregnancy in recreational and elite athletes : 2016/2017 evidence summary from the IOC expert group meeting, Lausanne. Part 5. Recommendations for health professionals and active women
Abstract 19234: Revascularization Improves the Levels and Organization of the Desmin Cytoskeletal System in the Gastrocnemius of Patients With Peripheral Artery Disease
Authors: PanagiotisKoutakis, George PCasale, EvlampiaPapoutsi, Julian Kyung-SooKim, DimitriosMiserlis, GlebHaynatzki, Holly KDeSpiegelaere, HernanHernandez, Constance JMietus, Duy MHa, PetrosKarvelis, ZhenZhu, NikolaosTsigkas, Yiannis SChatzizisis, Iraklis IPipinos
Journal: Circulation (2016)

Introduction:  Patients with peripheral artery disease (PAD) develop a myopathy in their ischemic limbs which is characterized by myofiber degeneration, mitochondrial dysfunction and impaired leg function. Degenerated myofibers have cytoskeletal abnormalities the best described of which is a disorganized accumulation of desmin filaments. The degree of disruption of the desmin system has been associated with altered myofiber morphology, decreased mitochondrial respiration, reduced calf muscle strength and decreased walking performance.   Hypothesis:  We hypothesized that the levels and organization of desmin in the myofibers of the gastrocnemius of PAD patients improve after revascularization and correlate with increases in mitochondrial respiration and calf muscle strength.   Methods:  Gastrocnemius biopsies were collected from 32 PAD patients, before and six months after revascularization. Accumulation and organization of desmin protein in myofibers were determined by quantitative fluorescence microscopy and desmin gene transcripts were quantified by rtPCR of RNA in biopsy homogenates. We evaluated the effects of revascularization on these parameters and their association with ischemic window (a measure of lower limb hemodynamic limitation), mitochondrial function determined by respirometry, and calf muscle strength.   Results:  Revascularization reduced the abnormal accumulation of disorganized desmin protein and gene transcripts in the PAD gastrocnemius. The ischemic window, myofiber morphology, mitochondrial respiration and calf muscle strength were significantly improved after revascularization. After revascularization, the decreased desmin expression was associated with a more structured appearance of the protein, suggesting a return to the normally filamentous structure. These changes in desmin correlated with improved mitochondrial function and increased calf muscle strength.   Conclusions:  Revascularization operations improve the levels and organization of the desmin filaments in the gastrocnemius of patients with PAD and these changes correlate with improved mitochondrial function and calf muscle strength.
An ounce of prevention is better than a pound of cure: shouldn’t we be doing EVERYTHING to reduce sports injury incidence and burden?
Authors: Adam Gledhill, Dale Forsdyke
Journal: British Journal of Sports Medicine (2018)

Given the impact of sports injury on athlete health, well-being and performance, reducing the incidence and burden of injuries is a priority for clinicians.1 As the causes of sports injuries are multifactorial, it is incumbent on multidisciplinary teams to design injury prevention programmes that address and modify these different factors.1 2 Despite this, it is uncommon that psychological components are included as part of injury prevention programmes. This is often, in part, attributed to a lack of confidence in integrating psychological techniques into programmes, concerns over the quality of evidence base or stigmas attached to the roles of sport psychology in sport.3 Consequently, the aims of this editorial are to first make a rationale for the inclusion of sport psychology interventions within injury prevention programmes and second suggest types of interventions that could be included as part of a multidisciplinary injury prevention programme.

Psychosocial characteristics are associated with an increased risk of injury and/or increased injury time-loss, with the link between psychosocial stress, stress responses and injury risk perhaps the most widely cited and recognised.4 The potential mechanisms behind these include psychophysiological, neurocognitive and/or behavioural changes, which may increase the risk of acute or overuse injuries. This being said, the link with overuse injuries is currently …
AB0318 Are patients experiencing different sort of fatigue depending on the type of chronic rheumatism?
Authors: W. Hamdi, M. Boudokhane, I. Cherif, D. Kaffel, K. Maatallah, M. Kchir
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Fatigue is frequently reported by patients with inflammatory chronic diseases as well as in mechanical rheumatologic disorders. But it's not recognised and treated as priority by clinicians. It is necessary toidentify the frequency of this symptom and to determinate it's impact on the quality of life of patient. <h3>Objectives</h3> We aimed to assess andto compare the frequency and the intensity of fatiguebetween inflammatory and degenerative chronic rheumatologic diseases, and to identify the factors correlated with fatigue in these diseases. <h3>Methods</h3> We conducted a cross-sectional study during 1 year including Tunisian patients with chronic inflammatory rheumatism (rheumatoid arthritis: RA according to the criteria ACR 1987 and axial spondyloarthritis: AS according to modified NEW YORK criteria)and patients with mechanical disorders (chronic low back pain and primitive knee osteoarthritis). Fatigue was assessed by the chalder questionnaire including physical and mental fatigue. <h3>Results</h3> We collected 120 patients with chronic inflammatory rheumatism (group 1) and 80 patients withmechanical disease (group2). Group 1 was composed of 70 RA and 50 AS including 65 women and 55 men. The average age was 46.95 [18.75]. Group 2 was composed of 40 chronic low back pain and 40 knee osteoarthritis including 48 women and 32 men. The average age was 51.95 [18.82]. Fatigue was more significantly observed in group 1 than in group 2: 8.40% vs 5.54% (p=0.000). Mental and physical fatigue was noted in 2.1% and 6.25% in group 1% and 1.0% and 4.49% in group 2, respectively. The risk factors for fatigue were in theRA thetender and swollen joint count, the DAS 28 and the HAQ. In AS, factors associated to fatigue were the visual scale of pain, BASFI, BASDAI, ASDAS<sub>ESR</sub> and CRP. In the chronic low back pain fatigue was associated by the functional impairment assessed by the Eiffel questionnaire. Finally knee in osteoarthritis fatigue was associated to Lequesne index and radiological stage. <h3>Conclusions</h3> Fatigue seems to be a frequent symptom in rheumatic diseases and mostly associated to severity and activity of the disease. <h3>Disclosure of Interest</h3> None declared
Direct pericyte-to-neuron reprogramming via unfolding of a neural stem cell-like program
Authors: Marisa Karow, J. Gray Camp, Sven Falk, Tobias Gerber, Abhijeet Pataskar, Malgorzata Gac-Santel, Jorge Kageyama, Agnieska Brazovskaja, Angela Garding, Wenqiang Fan, Therese Riedemann, Antonella Casamassa, Andrej Smiyakin, Christian Schichor, Magdalena Götz, Vijay K. Tiwari, Barbara Treutlein, Benedikt Berninger
Journal: Nature Neuroscience (2018)
<i>PIK3CA</i> Mutations in Hormone Receptor–Positive Breast Cancers
Authors: Vered Stearns, Ben Ho Park
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal